Modulation of Bifidocentric Dysbiosis Through Bifidobacterium Bifidum PRL2010 Supplementation in Caesarian-born Infants

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-01-05

Study Completion Date

2021-05-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is aimed to manipulate the composition of the intestinal flora of the infants born by caesarian section through the administration of the probiotic strain "Bifidobacterium bifidum PRL 2010", in order to evaluate its effects on gut dysbiosis during the first 6 month of life.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Lactobacillus Kefiri LKF01 (DSM32079) in Newborns Born by Caesarian Section

NCT03154866

Caesarean Section;Stillbirth Microbial Colonization

UNKNOWN PHASE4

Probiotic Supplementation in the Term Newborns Delivered by Caesarean Section

NCT03657485

Microbiota, Cesarean Section, Probiotics, Dysbiosis

COMPLETED NA

Cesarean Section Study

NCT01992497

Diarrhea Atopic Dermatitis

COMPLETED NA

Effect of an Infant Formula With Synbiotics in Infants Born Via Caesarean Section

NCT04991792

Gut Microbiota

COMPLETED NA

Impact of Probiotics Supplement on the Gut Microbiota in Caesarean-born Infants

NCT05086458

Gut Microbiota

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

There has been increasing interest in the field of human microbiome, considering its impact on health and diseases. The gastrointestinal tract represents the most heavily inhabited organ with microorganisms, counting 10 times the total number of human cells; for this reason, the gut microbiome has recently been referred as a proper organ. Intestinal microbial composition is unique for each individual and it is influenced by numerous factors, of which delivery mode is an important one with gestational age of the newborn, type of feeding and intrapartum or neonatal antibiotic therapy. Recent reports suggest that dysbiosis secondary to delivery mode affects the subsequent regulation of immune response and may be associated with several pathologic conditions, for example allergic diseases or obesity. Moreover, gut microbiome seems to impact on neurodevelopment during first six months of life. Bifidobacteria is the most represented group of intestinal microbiota in the newborn, followed by Enterobacteria, and it plays an important role in the infant gut. This includes the fundamental function performed by Bifidobacterium bifidum: it supplies the nutritional material to the rest of the microbial community, particularly Bifidobacterium breve and Bifidobacterium longum infantis that are the other typical bifidobacteria of the newborn. It is a powerful metabolizer of the intestinal mucus and the HMOs (Human Milk Oligosaccharides) present in breast milk. Thanks to its exocitable enzymes, the degradative catabolism occurs in the intestinal environment. Thus, B. bifidum favour the increase in intestinal richness and biodiversity (9), which correlates with the host's state of health. However, bifidobacteria is reduced in infants born by cesarean delivery.

Aim of the study is to assess if the Bifidobacterium Bifidum PRL2010 supplementation effectively ameliorat bifidocentric dysbiosis due to the delivery mode and we want to confirm this by analyzing fecal microbiota in caesarean birth infants.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Disbiosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Probiotic Bifidobacterium Bifidum PRL2010

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Probiotic Bifidobacterium Bifidum PRL2010

Participants in this group will receive probiotic Bifidobacterium Bifidum PRL2010 supplementation from the time of discharge to a daily for the 6 months

Group Type EXPERIMENTAL

Probiotic Bifidobacterium Bifidum PRL2010

Intervention Type DIETARY_SUPPLEMENT

Probiotic supplement

Control

Participants in this group will not receive probiotic probiotic supplementation

Group Type ACTIVE_COMPARATOR

Control group

Intervention Type OTHER

No probiotic supplementation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Probiotic Bifidobacterium Bifidum PRL2010

Probiotic supplement

Intervention Type DIETARY_SUPPLEMENT

Control group

No probiotic supplementation

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy infants born by caesarian delivery
* Parents informed written consent

Exclusion Criteria

* Suspension of the administration of the probiotic strain for a period of time exceeding 7 days
* Interruption of the administration of the probiotic strain before the completion of the sixth month
* Replacement of Bifidobacterium bifidum PRL2010 with another strain
* Refusal to collect the fecal sample expressed by parents
* Major congenital birth deformities
* Acute illness at enrollment
* Any condition affecting food intake or metabolism
* Maternal mental and psychosomatic diseases

Minimum Eligible Age

1 Month

Maximum Eligible Age

1 Year

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes